Lanreotide Acetate recalls
Lanreotide Acetate products have been recalled 3 times, most recently on 15 Apr 2026. The recalling company is usually Cipla USA. The most common reason is sterility.
Total recalls3since 2026
Last 12 months3reported
Class I00% of total
Ongoing3latest 15 Apr 2026
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 0 0%Class II 3 100%Class III 0 0%
Why lanreotide acetate is recalled
Companies
Product types
By year
Ongoing lanreotide acetate recalls
3 active| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Lanreotide Injection, 120 mg* recalled by Cipla USALanreotide Acetate | Cipla USA | Sterility | Nationwide |
| Drug | CLASS II | Lanreotide Injection, 120 mg recalled by Cipla USALanreotide Acetate | Cipla USA | Sterility | Nationwide |
| Drug | CLASS II | Lanreotide Injection, 120 mg/ per pre-filled syringe recalledLanreotide Acetate | Cipla USA | Particulate Matter | Nationwide |
All lanreotide acetate recalls, newest first
3 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Lanreotide Injection, 120 mg* recalled by Cipla USALanreotide Acetate | Cipla USA | Sterility | Nationwide |
| Drug | CLASS II | Lanreotide Injection, 120 mg recalled by Cipla USALanreotide Acetate | Cipla USA | Sterility | Nationwide |
| Drug | CLASS II | Lanreotide Injection, 120 mg/ per pre-filled syringe recalledLanreotide Acetate | Cipla USA | Particulate Matter | Nationwide |
About this list
Records come from FDA enforcement reports and USDA FSIS notices, grouped by normalised name. A company operating under several names may appear more than once.